BeOne Medicines Agreement: BeOne Medicines Ltd has entered into an agreement to sell its royalty rights on Amgen’s IMDELLTRA® for up to $950 million to Royalty Pharma, receiving an upfront payment of $885 million.
Royalty Structure: BeOne will retain a share of royalties on annual sales exceeding $1.5 billion and maintain rights to other assets under its collaboration with Amgen, including xaluritamig.
IMDELLTRA Overview: IMDELLTRA is a first-in-class immunotherapy approved for extensive-stage small cell lung cancer (ES-SCLC), targeting DLL3 on tumor cells and activating T cells to kill these cancer cells.
Company Commitment: BeOne Medicines aims to improve access to innovative cancer treatments globally, supported by a growing team and diverse therapeutic pipeline.
ONC
$306.05+Infinity%1D
Analyst Views on ONC
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 397.66 USD with a low forecast of 362.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast ONC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ONC is 397.66 USD with a low forecast of 362.00 USD and a high forecast of 424.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 304.310
Low
362.00
Averages
397.66
High
424.00
Current: 304.310
Low
362.00
Averages
397.66
High
424.00
Truist
Buy
initiated
$400
2025-11-24
Reason
Truist
Price Target
$400
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of BeOne Medicines with a Buy rating and $400 price target. The firm expect Brukinsa's revenue stream to sustainably support the company's operations and drive BeOne Medicines toward the guided positive free cash flow by 2025, the analyst tells investors in a research note. The company's leadership position in CLL - chronic lymphocytic leukemia - is well-solidified by Brukinsa's differentiation and the franchise's comprehensive growth strategy, including proprietary next-wave assets such as sonrotoclax and BTK CDAC, Truist added.
RBC Capital
Outperform
maintain
$395 -> $408
2025-11-18
Reason
RBC Capital
Price Target
$395 -> $408
2025-11-18
maintain
Outperform
Reason
RBC Capital raised the firm's price target on BeOne Medicines to $408 from $395 and keeps an Outperform rating on the shares. The Ziihera phase III HORIZON-GEA update clears the way for a potential 1L approval in combination with Tevimbra and chemotherapy and adds incremental upside to shares, the analyst tells investors in a research note.
Morgan Stanley
Sean Laaman
Overweight
maintain
$185 -> $205
2025-11-17
Reason
Morgan Stanley
Sean Laaman
Price Target
$185 -> $205
2025-11-17
maintain
Overweight
Reason
Morgan Stanley analyst Sean Laaman raised the firm's price target on Jazz Pharmaceuticals (JAZZ) to $205 from $185 and keeps an Overweight rating on the shares. Jazz reported positive topline results for the HERIZON-GEA-01 trial evaluating Ziihera, a bispecific HER2-directed antibody, in combination with chemotherapy, with or without BeOne Medicine's (ONC) PD-1 inhibitor Tevimbra, as first-line treatment for HER2-positive locally advanced or metastatic GEA, but and while limited details were provided, Jazz indicated a highly competitive profile ahead of the sBLA submission in 1H26, the analyst tells investors in a research note. Ziihera plus chemotherapy and Ziihera plus tislelizumab and chemotherapy demonstrated highly statistically significant and clinically meaningful improvements in progression-free survival compared to the control arm, positioning Ziihera as a potential new standard of care for first-line HER2-positive GEA, replacing trastuzumab in this setting, the firm says.
Jefferies
Buy
maintain
$398 -> $420
2025-11-17
Reason
Jefferies
Price Target
$398 -> $420
2025-11-17
maintain
Buy
Reason
Jefferies raised the firm's price target on BeOne Medicines to $420 from $398 and keeps a Buy rating on the shares following a fireside chat and investor breakfast with management in London. The firm notes that management believes its chronic lymphocytic leukemia franchise will deliver "best-in-class" therapy to the full spectrum of CLL market. BeOne is advancing solid tumor pipeline at full speed with data in 2026, Jefferies told investors in a research note.
About ONC
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
